Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
In the high-stakes world of biotech, cash runway and clinical trial data timing can make or break a company. With an increasing number of biotechs facing financial cliffs shortly after key data readouts, a new class of “financial zombie” companies is emerging—entities that are neither fully alive nor fully dead, surviving with limited cash and assets that remain stuck in development purgatory. This growing phenomenon is reshaping the reverse merger landscape, raising questions about which type of shell company is more valuable: one with cash but no assets, or one with a promising asset but no cash.
📣🎙️ TODAY’S POCAST:
[ 0:00 ] Intro
[ 0:30 ] Financial zombies
[ 1:30 ] Recent headwinds in biotech
[ 3:20 ] Intro to reverse mergers
[ 4:30 ] Reverse merger benefits for private biotechs
[ 6:00 ] Benefits for public shell biotechs
[ 7:20 ] Reverse mergers + PIPEs
[ 8:30 ] Conclusion
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Cash Runway Crisis and Reverse Mergers